Zobrazeno 1 - 10
of 10
pro vyhledávání: '"H. Roschitzki-Voser"'
Autor:
Johan Vansteenkiste, Amanda Tufman, M. Guckenberger, Dirk De Ruysscher, Miklos Pless, N. Andratschke, Maarten Lambrecht, Alex Martinez-Marti, Antonio Irigoyen, M. Kassapian, A.-C. Piguet, H. Roschitzki-Voser, Enriqueta Felip, Manuela Rabaglio-Poretti, Rolf A. Stahel, Urania Dafni, Claus Belka, H. Vees, Solange Peters, E. Nadal, A. Becker
Publikováno v:
Peters, S, Felip, E, Dafni, U, Belka, C, Guckenberger, M, Irigoyen, A, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Tufman, A, Lambrecht, M, Andratschke, N, Piguet, A C, Kassapian, M, Roschitzki-Voser, H, Rabaglio-Poretti, M, Stahel, R A, Vansteenkiste, J & De Ruysscher, D 2019, ' Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial ', Lung Cancer, vol. 133, pp. 83-87 . https://doi.org/10.1016/j.lungcan.2019.05.001
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Lung Cancer, 133, 83-87. Elsevier Ireland Ltd
Objectives: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in preclinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial.Material
Autor:
Zoi Tsourti, Nicolaus Andratschke, A. Becker, Enriqueta Felip, Ernest Nadal, Rolf A. Stahel, Matthias Guckenberger, H. Roschitzki-Voser, Ruth Álvarez, Adrian Gasca-Ruchti, Solange Peters, Urania Dafni, Maarten Lambrecht, H. Vees, Miklos Pless, Amanda Tufman, Johan Vansteenkiste, Alex Martinez-Marti, A.-C. Piguet, Dirk De Ruysscher
Publikováno v:
Peters, S, Felip, E, Dafni, U, Tufman, A, Guckenberger, M, Álvarez, R, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Lambrecht, M, Andratschke, N, Tsourti, Z, Piguet, A-C, Roschitzki-Voser, H, Gasca-Ruchti, A, Vansteenkiste, J, Stahel, R A & de Ruysscher, D 2021, ' Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC : Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14) ', Journal of Thoracic Oncology, vol. 16, no. 2, pp. 278-288 . https://doi.org/10.1016/j.jtho.2020.10.129
Journal of Thoracic Oncology, 16(2), 278-288. Elsevier Science
Journal of Thoracic Oncology, 16(2), 278-288. International Association for the Study of Lung Cancer
Journal of Thoracic Oncology, 16(2), 278-288. Elsevier Science
Journal of Thoracic Oncology, 16(2), 278-288. International Association for the Study of Lung Cancer
INTRODUCTION: The NICOLAS study is the first completed single-arm phase II trial in stage III NSCLC evaluating hierarchically first the safety and then the efficacy of adding nivolumab concurrently to standard definitive concurrent chemoradiotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3688b7e198f0cac9727399400a9dcdc8
https://research.vumc.nl/en/publications/5cbb09d1-f28c-41dc-82db-7737694694e0
https://research.vumc.nl/en/publications/5cbb09d1-f28c-41dc-82db-7737694694e0
Autor:
W.-D. Janthur, Solange Peters, R. Shah, E. Nadal, David Gilligan, Sanjay Popat, R. López Castro, H. Roschitzki-Voser, Arup Roy, S. Rusakiewicz, A. Pope, James Spicer, Alessandra Curioni-Fontecedro, Patricia Fisher, Igor Letovanec, Varvara Polydoropoulou, Mary O'Brien, Oliver Gautschi, A. Gasca-Ruchti, Rolf A. Stahel, Urania Dafni, R. García Campelo, Barbara Ruepp
Publikováno v:
Annals of oncology, vol. 31, no. 12, pp. 1734-1745
Background Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6f837ec9c55fa71b6f276b35f45c97
https://serval.unil.ch/resource/serval:BIB_0FC8052F2621.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_0FC8052F2621.P001/REF.pdf
Autor:
Niki Karachaliou, Zoi Tsourti, Bartomeu Massuti, Santiago Ponce Aix, Martin Früh, Miklos Pless, Paolo Bidoli, Núria Jordana-Ariza, Ariadna Balada-Bel, H. Roschitzki-Voser, Enriqueta Felip, Solange Peters, Mónica Garzón-Ibáñez, Roswitha Kammler, Ramon Palmero, Sinead Cuffe, Clara Mayo-de-las-Casas, Rafael Rosell, Sanjay Popat, Enric Carcereny, M.A. Molina-Vila, Oliver Gautschi, Beatriz García-Peláez, Rolf A. Stahel, Urania Dafni, Alessandra Curioni Fontecedro
Publikováno v:
Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Introduction: Longitudinal evaluation of mutations in blood samples was a prespecified secondary objective in the BELIEF trial of erlotinib and bevacizumab in advanced EGFR-positive NSCLC. Here, we report the testing results and explore the correlati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994673a7e864203d23813318e7ec156a
http://hdl.handle.net/10281/260723
http://hdl.handle.net/10281/260723
Autor:
H. Roschitzki-Voser, Gillian Price, Rolf A. Stahel, Sinead Cuffe, Urania Dafni, Sarah Danson, Barbara Ruepp, Linda Coate, Roger von Moos, Mariano Provencio, Oliver Gautschi, Miklos Pless, Katja Mohorcic, Margarita Majem, Delvys Rodriguez-Abreu, Lionel Falchero, Bartomeu Massuti Sureda, Andrea Luciani, Solange Peters, M. Cobo, Jose Garcia Sanchez, Ingel K. Demedts, Alessandra Curioni-Fontecedro, Kurt G. Tournoy, Baktiar Hasan, Michael Mark, A. Pochesci, Manuela Rabaglio, Niels Reinmuth, Christoph C. Zielinski, Mary O'Brien, Daniel Betticher, Ana Laura Ortega Granados, Benjamin Besse, Isabelle Monnet, Jose Antionio Macias, Teresa Moran, Jessica Menis
Publikováno v:
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
BASE-Bielefeld Academic Search Engine
Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-FISABIO. Repositorio Institucional de Producción Científica
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
BASE-Bielefeld Academic Search Engine
Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-FISABIO. Repositorio Institucional de Producción Científica
Introduction: Receptor activator of NF-kB ligand stimulates NF-kB-dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f11ec141e54ab0cd5ed8503a4a2a09f9
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6552
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6552
Autor:
Manuela Rabaglio, Enriqueta Felip, Rafal Dziadziuszko, Stephen P. Finn, Solange Peters, Zoi Tsourti, Wojciech Biernat, Rolf A. Stahel, Egbert F. Smit, H. Roschitzki-Voser, Urania Dafni, Juergen Wolf, Roswitha Kammler, Bartosz Wasąg, Barbara Ruepp
Publikováno v:
Dziadziuszko, R, Smit, E F, Dafni, U, Wolf, J, Wasąg, B, Biernat, W, Finn, S P, Kammler, R, Tsourti, Z, Rabaglio, M, Ruepp, B, Roschitzki-Voser, H, Stahel, R A, Felip, E & Peters, S 2019, ' Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP) ', Journal of Thoracic Oncology, vol. 14, no. 6, pp. 1086-1094 . https://doi.org/10.1016/j.jtho.2019.02.017
Journal of Thoracic Oncology, 14(6), 1086-1094. International Association for the Study of Lung Cancer
Journal of Thoracic Oncology, 14(6), 1086-1094. International Association for the Study of Lung Cancer
Introduction Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. Activity of various biologically distinct HER2 inhibitors, including t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b84022a336811fdf3026b3a3589e3be
https://research.vumc.nl/en/publications/078b83cc-f9da-4eff-852f-c47a40492f4f
https://research.vumc.nl/en/publications/078b83cc-f9da-4eff-852f-c47a40492f4f
Autor:
S. Rusakiewicz, R. Shah, Ernest Nadal, David Gilligan, Sanjay Popat, Solange Peters, Patricia Fisher, A. Pope, Alessandra Curioni-Fontecedro, V. Polydoropoulou, R. López Castro, Mary O'Brien, O. Gautschi, Rolf A. Stahel, James Spicer, H. Roschitzki-Voser, Arup Roy, R. García Campelo, W.-D. Janthur, Barbara Ruepp
Publikováno v:
Web of Science
Background MPM is an aggressive malignancy of increasing prevalence and poor prognosis. At relapse after platinum-based (pb) CT, single agent CT is commonly used and single arm trials of immune checkpoint inhibitors have demonstrated encouraging acti
Autor:
Antonio Irigoyen, Zoi Tsourti, N. Andratschke, Enriqueta Felip, Manuela Rabaglio-Poretti, Solange Peters, H. Roschitzki-Voser, E. Nadal, H. Vees, Dirk De Ruysscher, Miklos Pless, M. Guckenberger, Maarten Lambrecht, Johan Vansteenkiste, A. Becker, Amanda Tufman, Rolf A. Stahel, Urania Dafni, Alex Martinez-Marti, A.-C. Piguet
Publikováno v:
Annals of Oncology. 30:v591
Background NICOLAS is a single-arm phase II trial in stage III NSCLC. The safety analysis has earlier provided evidence that nivolumab administration concurrently to chemo-radiotherapy (CRT) is safe and tolerable, with respect to the occurrence of cl
Autor:
Solange Peters, Enriqueta Felip, Antonio Irigoyen, Alex Martinez Marti, Claus Belka, H. Roschitzki-Voser, A.-C. Piguet, Annemarie Becker, M. Kassapian, Johan Vansteenkiste, Maarten Lambrecht, Rudolf M. Huber, Rolf A. Stahel, Urania Dafni, Nicolaus Andratschke, Dirk De Ruysscher, Adriana Gasca-Ruchti, Matthias Guckenberger, Ernest Nadal-Alforja
Publikováno v:
Journal of Clinical Oncology. 36:8510-8510
8510Background: The feasibility of combined chemo-radiotherapy (chemo-RT) and concurrent PD-1 inhibition is of high scientific interest and has shown promising results in pre-clinical models. So fa...
Autor:
Rosita Kammler, Rolf A. Stahel, Urania Dafni, Barbara Ruepp, Stephen P. Finn, Egbert F. Smit, Enriqueta Felip, Wojciech Biernat, Manuela Rabaglio-Poretti, Juergen Wolf, Solange Peters, Bartosz Wasąg, Rafal Dziadziuszko, Zoi Tsourti, H. Roschitzki-Voser
Publikováno v:
Journal of Clinical Oncology. 35:9070-9070
9070 Background: HER2mutations are identified in about 2% of lung adenocarcinomas and are critical for lung carcinogenesis. Afatinib is a selective and irreversible erbB family blocker with a manageable toxicity profile and promising results in small